COVID-19 MESSAGE FROM BMMSA

Our first priority is the health, wellness and safety of everyone who walks through our doors.

Bryn Mawr Medical Specialists Association is open for medically necessary office visits and procedures only. BMMSA as a corporation is taking all necessary precautions and following public health safety guidelines in regards to the COVID-19 pandemic.

TeleMedicine appointments are now available. Please contact your physicians office for eligibility, additional information, and with any concerns or questions.

As per order of the Commonwealth of Pennsylvania, any person entering our office building is required to wear a face mask at all times. Patients will not be permitted to enter the building without a face mask.

All patients should expect to be phone screened by Bryn Mawr Medical Specialists Association staff for COVID-19 symptoms or exposures prior to their appointment and again upon arrival. Patients should also expect to be temperature screened upon arrival in the office.

If your answer to any of the following questions is “Yes”, we ask that you call to reschedule your appointment.

In the past 14 days, have you developed any fever, cough or shortness of breath?
In the past 14 days, have you developed any of the following new symptoms?

  • Body aches or muscle pains?
  • Chills or repeated shaking with chills?
  • Headache?
  • Sore throat?
  • New loss of taste or of smell?
  • Have you, or anyone you have close contact with, been recently referred for COVID-19 testing?

In the past 14 days, have you traveled outside of PA? If “Yes”, please call the office to notify us of travel BEFORE your appointment. Patients recently returning from travel restricted states or countries will be asked to reschedule their appointment.

For the safety of our staff and other patients, patient family members or companions are not permitted at this time to accompany patients to their appointments (unless medically necessary or the patient is a minor). Bryn Mawr Medical Specialists Association respectfully asks family members or companions to wait outside or safely in their vehicle.

We encourage all of our patients to visit the CDC website and Main Line Health COVID-19 Response website to read more about everyday preventative measures and for the most up to date guidance regarding the Coronavirus (COVID-19). If you are concerned that you may have the Coronavirus (COVID-19), please contact your local Health Departments.

If you have any questions regarding our policy and your appointment, please call your doctor’s office.

Molly S. Stumacher, M.D.

Hematology/Oncology

Specialties

  • Hematology

    Board Certified in 2008
  • Oncology

    Board Certified in 2007

Location

Bryn Mawr Medical Arts Pavilion
825 Old Lancaster Road
Suite 440
Bryn Mawr, PA 19010
Phone: (610) 525-4511
Fax: (610) 525-8561

Education & Training

Medical School

Harvard Medical School, Boston, MA

Residency

Department of Medicine, Brigham and Women’s Hospital, Boston, MA

Fellowship

Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

Affiliations

  • Bryn Mawr Hospital
  • Lankenau Hospital
  • Paoli Hospital

Clinical/Dept Titles

Attending Physician

Research Experience

  • CD40 antibody for the treatment of advanced solid tumors (Phase I study), PI: Robert Vonderheide, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
  • CTLA4 antibody in the treatment of advanced breast cancer (Phase I study), PI: Susan Domchek, M.D., University of Pennsylvania Department of Hematology-Oncology, 2005-2006
  • The use of executive summaries in cancer patients’ consent to clinical trial enrollment (Phase II study), PI: Jane Weeks, M.D. and Steven Joffe, M.D., Dana Farber Cancer Institute, 2003

Publications

  • Vonderheide, RH, Flaherty KT, Khalil M, Stumacher MS, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
  • Stumacher, M, Domchek S. Update on chemoprevention in BRCA1and BRCA2 mutation carriers. Breast Cancer Online. 2005 Vol. 8 Issue 9.
Browse available departments: